EYEN.png
Eyenovia Announces $12 Million Registered Direct Offering
24 août 2023 18h47 HE | Eyenovia, Inc.
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for...
Eyenovia Logo 311 x 109.png
Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals
16 août 2023 06h00 HE | Eyenovia, Inc.
APP13007, if approved, may have an advantageous profile in dosing frequency and side effects while reducing the inflammation and pain associated with ocular surgery Further leverages Eyenovia’s...
Eyenovia Logo 311 x 109.png
Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update
10 août 2023 16h05 HE | Eyenovia, Inc.
Announced FDA approval of and first commercial sale of Mydcombi™, the only fixed dose combination of tropicamide and phenylephrine for mydriasis and the first FDA approved product to utilize the...
Eyenovia Logo 311 x 109.png
Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
09 août 2023 08h00 HE | Eyenovia, Inc.
NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray)...
Eyenovia Logo 311 x 109.png
Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10
07 août 2023 08h00 HE | Eyenovia, Inc.
NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray) for mydriasis and...
Eyenovia Logo 311 x 109.png
Eyenovia Announces First Commercial Sale of Mydcombi™
03 août 2023 08h00 HE | Eyenovia, Inc.
Represents the first FDA approved and commercially available fixed combination of tropicamide and phenylephrine for pupil dilation Validates Eyenovia’s proprietary Optejet® dispensing platform ...
Eyenovia Logo 311 x 109.png
Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes
26 juin 2023 08h00 HE | Eyenovia, Inc.
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company preparing for the launch of Mydcombi™ (tropicamide+phenylephrine...
Eyenovia Logo 311 x 109.png
Eyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023
01 juin 2023 08h00 HE | Eyenovia, Inc.
Presentation to highlight recent FDA approval of Mydcombi™ for mydriasis which leverages Eyenovia’s novel Optejet dispensing device Optejet represents the first true advancement in the topical...
Eyenovia Logo 311 x 109.png
Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update
11 mai 2023 16h05 HE | Eyenovia, Inc.
Announced FDA approval of Mydcombi™, a fixed dose combination of tropicamide and phenylephrine for mydriasis, the first FDA approved product to utilize the Optejet® Received feedback from FDA on...
Eyenovia Logo 311 x 109.png
Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform
08 mai 2023 08h00 HE | Eyenovia, Inc.
Represents the first FDA approved fixed-combination of tropicamide and phenylephrine for mydriasis Provides critical validation of key technology that is core to Eyenovia’s proprietary development...